View in EDS

Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65 years of age and older: A phase II, observer-blind, randomized, controlled trial.

Saved in:
Bibliographic Details
Title: Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65 years of age and older: A phase II, observer-blind, randomized, controlled trial.
Authors: Madan, Anuradha1 Anu.2.Madan@gsk.com, Ferguson, Murdo2, Rheault, Paul3, Seiden, David4, Toma, Azhar5 azhar.toma@mannaresearch.com, Friel, Damien6 damien.j.friel@gsk.com, Soni, Jyoti7, Li, Ping1 ping.li4@pfizer.com, Innis, Bruce L.1 bruce.2.innis@gsk.com, Schuind, Anne1
Source: Vaccine. Apr2017, Vol. 35 Issue 15, p1865-1872. 8p.
Database: Environment Complete
Description
ISSN:0264410X
DOI:10.1016/j.vaccine.2017.02.057